Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

Summary

The purpose of this study is to examine the safety and efficacy of quetiapine for generalized anxiety disorder patients who remain symptomatic despite treatment with paroxetine CR.

Timeline

Start

2004-02

Primary completion

2007-02

Completion

2007-11

Outcome

Met primary endpoint

registry Quetiapine, 25-400mg/Day Augmentation of Continued Paroxetine vs Placebo Augmentation of Continued Paroxetine; p <0.05; Mean Difference (Net) 2.3; t-test, 2 sided NCT00113295 ↗

Drugs

Indications